US Patent Issued to Beijing Friendship Hospital, Capital Medical University on May 13 for "Biomarker for predicting drug resistance of bruton's tyrosine kinase inhibitors and application thereof" (Chinese Inventors)

ALEXANDRIA, Va., June 12 -- United States Patent no. 12,297,434, issued on May 13, was assigned to Beijing Friendship Hospital, Capital Medical University (Beijing).

"Biomarker for predicting drug resistance of bruton's tyrosine kinase inhibitors and application thereof" was invented by Yiqun Che (Beijing), Junhao Wei (Beijing) and Xinyu Han (Beijing).

According to the abstract* released by the U.S. Patent & Trademark Office: "A biomarker for predicting drug resistance of a BTK inhibitor and an application thereof are provided in the present disclosure, relating to the technical field of biomedicine. The biomarker is SMPD1 or SPHK1; the drug resistance of BTK inhibitor refers to the drug resistance of diffuse large B cell lymphom cells to...